Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlobeImmune Gets A Shot In The Arm Thanks To Celgene Cancer Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Hepatitis C vaccine success validated technology and paved way for the deal.

You may also be interested in...



Drug Makers Designing Better Ingredients For Hep C Drug Cocktails

As the field of hepatitis C therapy opens up with the specifically targeted antiviral therapies for HCV, the combination of drugs used to treat the chronic disease will be in flux. While the likely key ingredients are pretty well known, and for the immediate future will retain an interferon/ribavirin backbone, a few smaller companies are starting to demonstrate what they can add to the mix

Drug Makers Designing Better Ingredients For Hep C Drug Cocktails

As the field of hepatitis C therapy opens up with the specifically targeted antiviral therapies for HCV, the combination of drugs used to treat the chronic disease will be in flux. While the likely key ingredients are pretty well known, and for the immediate future will retain an interferon/ribavirin backbone, a few smaller companies are starting to demonstrate what they can add to the mix

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009

Highlights from the Q2 2009 review of pharmaceutical and biotechnology dealmaking: In biopharma financing, the FOPO had a comeback bringing in $773 million with 11 transactions--a deal volume the public markets haven't achieved since Q1 2008. Cephalon and Dendreon led the pack, each with follow-on offerings exceeding the $100 million mark. There weren't the mega Big Pharma mergers done in previous months, however, there was a clear interest in generics as witnessed by Sanofi-Aventis' buyouts of two generics firms, and Watson and Novartis also getting in on the action, each through $1 billion+ acquisitions in this arena as well. As far as alliances were concerned, the top spot belongs to GlobeImmune, which granted Celgene exclusive worldwide rights to its {Targomen} cancer programs (including two clinical-stage candidates) in exchange for a potential $540 million pay day.Q2 also saw many companies shifting therapeutic focus to in-license products and candidates new to them in order to revive pipelines and beef up portfolios.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel